Candel Therapeutics (CADL) Accounts Payables (2020 - 2025)

Candel Therapeutics' Accounts Payables history runs 6 years deep, the most recent figure standing at $1.1 million for Q4 2025.

• In Q4 2025, Accounts Payables rose 376.37% year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at $1.1 million (up 376.37% YoY), while the FY2025 annual figure was $1.1 million, up 376.37% from the prior year.
• Accounts Payables came in at $1.1 million for Q4 2025 at Candel Therapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $2.0 million in Q2 2025 to a low of $237000.0 in Q4 2024.
• A 5-year average of $828210.5 and a median of $759000.0 in 2021 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables slumped 76.1% in 2022 and jumped 376.37% in 2025, its largest moves.
• Candel Therapeutics' Accounts Payables stood at $1.6 million in 2021, then plunged by 76.1% to $380000.0 in 2022, then rose by 11.05% to $422000.0 in 2023, then slumped by 43.84% to $237000.0 in 2024, then surged by 376.37% to $1.1 million in 2025.
• According to Business Quant data, Accounts Payables over the past three periods registered $1.1 million, $1.1 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison